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correlation was found with time to repedus~on (r=O.llO; ~~0.20). A significant correlation in UA patients significantly increased neutrophil apoptotic rate (36%; 21.47%. p=O.O06 vs 
was also observed between AEDV and peak creatine-kinase (p=O.O04; r=-0.649). baseline); moreover apoptotic rate following abciximab was not different from that 
CONCLUSIONS: The presence of an adequate, even though non-angiographically evi- observed in SA and healthy subjects. Conclusions. Our study demonstrates that Abcix- 
dent collateral flow may reduce microvascular damage in the setting of AMI treated with imab increases PMN apoptotic rate in patients with severe UA. Such increased blood 
primary PTCA, thus favouring ContractlIe recovery and preventing left ventricular remod- clearance of circulating PMN represents a novel anb-inflammatory mechanism of Abcix- 
cling. imab. 
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Background: One of the challenges for gene therapies IS to be able to switch on or off 
gene expression, ideally by a pathophysiological stimulus. For the purpose of treating 
myocardial ischemia, we have used hypoxia as the stimulus. Hypoxia-inducible factor 1 a 
(HIF-la ) is the master regulator for hypoxia rasponsas. Its protein stability is regulated 
by its oxygen-dependent degradation (ODD) domaln, which triggers a proteosome-medi- 
ated degradation only under normoxia. Therefore, we invented an oxygen-sensitive regu- 
lator (OSR) as hypoxic gene switch by fusing the ODD domain in between the DNA 
binding domain of yeast GAL4 and the activation domain of ~65. 
Method: The OSR recognizes and activates a minimal promoter containing GAL4 
upstream activating sequences. Three reporter genes. luciferase. p -galactosldase and 
secreted alkaline phosphatase were inserted downstream of this minimal promoter, 
respectively. The myosin light chain-2v (MLC-2~) promoter was used to restrict the 
expression of OSR in the heart. The plasmids were co-transfected into embryonic and 
adult rat cardiomyocyies and tested under hypoxia (1% Q or 0.5% 02) and normoxia 
(20% 0,). 
Results: After transfection, the expression of tuciferase was induced under hypoxia 3 to 
6 fold in embryonic cardiomyocytes and 16 fold in adult cardiomyocytes. When three dlf- 
ferent reporter plasmids were co-transfected with OSR. all of them were up-regulated 16 
to 18 fold by hypoxia. The OSR could rapidly turn on gene expression with the hypoxic 
stimulus and turn it off after normal air was restored. Furthermore, the OSR dramatically 
amplified the power of the MLC-2~ promoter up to 300-fold but still maintained its cardiac 
specificity. 
Conclusion: The OSR invented in current study is a novel oxygen sensor and gene 
amplifier. more effective than either HIF-1 or hypoxia response element in switching on 
and amplifying a cardiac specific promoter. It can be adapted into an adeno-associated 
virus mediated ‘“vigilant vector” to deliver multiple protective genes to the heart, such as 
heme oxygenase-1, superoxide dismutase. and VEGF, and simultaneously turn them on 
in response to ischemla and off in normoxia. 
BACKGROUND: Cardiac troponln-I (cTnl) IS a more specific and sensitive biomarker 
than creatine kinase MB (CK-MB) for detection of myocardial damage. However, the 
impact of cTnl versus CK-MB on the rates of diagnosis of acute myccardial infarction 
(AMI) is unclear. 
METHODS Seven hundred seventy-six consecutive hospital admissions for suspected 
acute coronarv syndrome (ACS) to an urban acute care hospital over a four month period 
were analyzed Patients were aged 16 to 84, residents of the seven-county Twin Cities 
metropolitan area. and had at least two separate sets of plasma biomarkers sent to the 
laboratory for evaluation of possible AMI during each hospital admission. cTnl and CK- 
MB assays (Dade Dimension) were performed concurrently. 
RESULTS: Using the 10% coefficient of variation (CV) cut-off adopted by the hospital 
(cTnl > 0.3 ng/mL and CK-MB > 5.0 ng/mL), 116 (14.9%) of the 776 consecutive ACS 
admlssions had positive cTnl. Of these, only 58 (50%) had positive CK-MB. Using a 99th 
percentile cut-off (cTnl > 0.1 ng/mL and CK-MB > 4.0 ng/mL) instead of the 10% CV cut- 
off would increase the number of CT&positive, CK-MB-negative admissions by 123%. 
Using the receiver operator charactenstic curve-derived cut-off (cTnl > 0.6 ng/mL and 
CK-MB > 7.0 ng/mL) Instead of the 10% CV cut-off would decrease the number of cTnl- 
positive, CK-MB-negative admissions by 27%. 
CONCLUSION: Rates of diagnosis of AMI as determined by plasma biomarkers are sub- 
stantially increased by criteria utilizmg cTnl compared to those utilizing CK-MB. Utilizing 
lower reference cut-offs for these plasma biomarkers markedly increases the rates of 
cTnl-positive, CK-MB-negative cases. 
1096-108 Reconstituted High-Density Lipoprotein Restores 
Endothelial Function in Acute Coronary Syndrome 
Remv Chenevard, David Huerlimann, Markus Bechir, lrmgard Andresen, Frank 
Ruschitzka. Thomas F. Luscher. Georg Nell, University Hospital, Zurich, Switzerland 
disease. In this study we tested the hypothesis wether reconstituted high density lipopro- 
tein (rHDL) can alter endothelial function I” patients diagnosed with ACS. 
Methods Measurements Included (I) venous occlusion plethysmography with acetylcho- 
Bapkground Acute Coronary Syndrome (ACS) is associated with severe impairment of 
endothellal function which correlates well with clinical outcome. Elevated levels of high 
density lipoprotein have long been recognized as a protective factor in cardiovascular 
Giuseppe Calvefi Carlo N. Dajelll Ermolli, Ylenia Beltelli, Salvatore Calco, Albert0 
Limido, Jorge A. Uriarte-Salerno, University of Insubria, Varese. Italy 
Can Preinfarction Angina Limit Infarct Size in Patients 
With a First Q-Wave Myocardial Infarction Undergoing 
Primary Percutaneous Coronary Angioplasty? 
1096-l 11 
line (ACH) as an endothellum-dependent vasodilator, nitroglycerine (NG) as direct dilator 
of vascular smooth muscle cells, results beeing expressed as ml flow per 100 ml tissue; 
and (2) positron emission tomography (PET) to assess myocardial perfusion at rest and 
during stress with adenosine, results beeing expressed as ratio of flow under stress/at 
rest. Experiments were performed before and after infusion of 80 mg rHDL per kg body 
weight and took place wlthin 7 days after diagnosis of ACS. All patients underwent percu- 
taneous coronary intervention prior to randomization and were an current standard med- 
ical treatment. 
Results 16 patients were included. ACH induced flow increased significantly after Infu- 
sion of rHDL (6.5 mllmin *2 to 8.0 mlimin ~2.4. p=O.O45). NG-induced blood flow too 
increased under rHDL as did PET assessed coronary flow reserve (11 mllmin e2.6 to 
14.5 mllmin +2.7. p=O.O3 and 1.2 +O.l versus 2.0 kO.3, p=O.O18). Hemodynamlc param- 
eters like mean arterial pressure and heart rate remained unchanged (73 mmHg versus 
72 mmHg and 64 bpm versus 64 bpm). rHDL infuston was well tolerated in all patients. 
Conclusions rHDL on top of standard treatment increased vascular reagibility I” patients 
diagnosed with ACS. rHDL possesses pkitropic effects, its anti-inflammatory component 
may be the most potent as acute inflammation - measured for example as c-reactive 
protein IS a diagnostic key factor in the outcome of ACS. Despite endothelial function 
being an excellent surrogate, prospective clinical trials are needed in order to unravel the 
true potential of rHDL as novel treatment option. 
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Background. Activated neutrophils have been found !n the coronary circulation of unsta- 
ble angina (UA) patients. Neutrophil apoptosis. a key mechanism to control the intensity 
of the acute inflammatory response, is markedly reduced in unstable angina (UA) 
BACKGROUND: In patients with acute myocardial infarction (AMI), preinfarction angina 
(PA) promotes protective effects in the ischaemic myocardium, reducing the necrosis 
extension, but its impact in patients treated with primary percutaneous coronary angio- 
plasty with stem deployment (PTST) is not already defined. 
METHODS: We studied 163 patients (mean age 66.4 years, 26.6% female), hospitalised 
in our coronary care unit for a first Q wave AMI and treated with successful primary PTST 
on the culprit lesion (TIM13 flow restored). 2D-echocardiographic left ventricular ejectlon 
function (LVEF), assessed in the first 24 hours after PTST, was successively compared 
with LVEF at hospital discharge (after 7-10 days). Myocardial reperfusion was consid- 
ered successful when at least three of the following criteria were reached (MR.score): (I) 
early ST-resolution >50% or (2) early T-wave inversion in the frst 90 men after PTST. (3) 
reperfusion ventricular arrhythmias, (4) CK and CK-MB time-to-peak <I2 hours. Major 
Adverse Cardiac Events (MACES) were evaluated at hospital discharge. 
RESULTS: In the study population patients with PA were 75 (mean age 70.1 years 
30.7% female). No differences in age, sex or prevalence of coronary risk factors were 
ewdenced. When PA was present, higher mean MR-scores (2.47 vs 1.51 p=O.O420) and 
successful reperfusion (53.3% vs 36.1% p=O.O207) were reached, especially in associa- 
tion with early T-wave inversion I” the first 90 minutes (61.3% vs 41.7% p=O.O089). LVEF 
on admission was similarly impaired in both PA and non-PA group (39.3% vs 43.6% 
p=ns) but Incidence of early left vantricular expansion was sensibly inferor (I .4% vs 
11.1% p=O.O346). At pm-discharge 2D-echo control. per cent improvement of LVEF was 
demonstrated superior (+26.5% vs +14.8% p=O.O276), while in-hospital MACE was ag- 
nificantly limited (8.0% vs 18.5% p=O.O450). 
CONCLUSIONS: Our results suggest that in patients with AMI treated with primary 
PTST, PA induces protective effects In the ischemic myocardium, probably due to myo- 
cyte preconditioning which favours more rapid and effective reperfusion and limits infarct 
size, improving left ventricular function and in-hospital prognosis. 
1096-112 Role of Endothelial Nitric Oxide Synthase in Arterial 
Remodeling in Heart Failure 
patients. Abciximab modulates neutrophll activation, however its effect on neutrophil 
apoptosis !n UA patients has not been yet Investigated. Methods. We investigated spon- Mohamed A. Gaballa, Steven Goldman, University of Arizona Saner Heart Center, 
taneous PMN apoptosis I” 6 patients with Braunwald class IIIB UA, III 12 stable angina Tucson, AZ, Southern Arizona VA Health Care System, Tucson. AZ 
(SA) patients and 12 healthy subjects. In UA patients, PMN apoptosis was also a&- To examine the role of nitric oxide (NO) in systemic arterial remodeling in congestive 
ated 30 min after 0.25 mg/Kg IV bolus of Abciximab. Apoptosls was evaluated by flow heart failure (CHF) ,n viva, we measured arterial morphology in the resistance hindltmb 
cytometry (Annexln V-FITC, Immunotech, Marseille) after PMN isolation from peripheral vasculature in the rat coronary altery ligation model of CHF 5 days after adenoviral-medi- 
blood samples (gradient centrifugation, Polymorphprep, Nicomed). Results (median; ated gene transfer of endothelial nitric oxide synthase (eNOS). The presence of CHF 
range). PMN apoptotic rate was signlfvxntly lower in UA (18%; 11.34%). than in SA was documented with increases (PcO.05) in left ventricular (LV) end-dk&olic pressure, 
(45%; 6-81% p=O 02) and healthy subjects (50%; 25.62%, p<O.OOl). Bolus of Abciximab decreases LV systolic pressure. and LV dP/dt. In the resistance vessels, of CHF rats, 
